Key result
Prenyltransferase inhibitors have evolved from their initial use as cancer therapeutics to expanded applications for other diseases, including progeria, hepatitis C and D, and parasitic infections.
Prenyltransferase inhibitors, initially developed for cancer, show promise in treating a variety of other diseases including progeria and parasitic infections.
The posttranslational modification of protein prenylation is a covalent lipid modification on the C-terminus of substrate proteins that serves to enhance membrane affinity. Oncogenic proteins such as Ras have this modification and significant effort has been placed into developing inhibitors of the prenyltransferase enzymes for clinical therapy. In addition to cancer therapy, prenyltransferase inhibitors have begun to find important therapeutic uses in other diseases, including progeria, hepatitis C and D, parasitic infections, and other maladies. This review will trace the evolution of prenyltransferase inhibitors from their initial use as cancer therapeutics to their expanded applications for other diseases.
No takes yet. Share an insight, caveat, or question.
Ochocki et al. (2012) conducted a review in Cancer, progeria, hepatitis C and D, parasitic infections. Prenyltransferase inhibitors was evaluated. Prenyltransferase inhibitors have evolved from their initial use as cancer therapeutics to expanded applications for other diseases, including progeria, hepatitis C and D, and parasitic infections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: